Literature DB >> 2253796

Adrenocortical carcinoma. A retrospective study of a rare tumor with a poor prognosis.

S Gröndal1, B Cedermark, B Eriksson, L Grimelius, R Harach, A Kristoffersson, J Rastad, P Udén, G Akerström.   

Abstract

A retrospective study was performed on 54 patients diagnosed as having adrenocortical carcinoma during 1974-1983. The initial symptoms were often diffuse: abdominal pain, weight loss, or fever, and more than 60% of the patients showed no evidence of overproduction of hormone. The median tumor diameter was 13 cm and almost half of the tumors had metastasized at diagnosis. A radical tumor resection could be performed in less than 50% of the patients, and at histopathological re-examination some tumors were not conclusively verified as malignant. Capsular invasion, nuclear pleomorphism and mitoses were found more commonly in patients who succumbed to the disease. Seven of 29 patients treated with chemotherapy showed an objective response and two of them are still alive and free of disease. The overall 5-year-survival rate was 19%, compared with 45% for patients with radically resected tumors. Patients with no biochemical signs of overproduction of adrenocortical hormone appeared to have a better prognosis than those with hormone excess. Together with increased use of ultrasound and computed tomography, a urinary steroid profile might hopefully contribute to earlier discovery of these often clinically silent tumors. However, it remains to be determined whether these diagnostic improvements, together with more aggressive surgery and adrenolytic chemotherapy, can improve the poor prognosis.

Entities:  

Mesh:

Year:  1990        PMID: 2253796

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

Review 1.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

2.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 3.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 4.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

5.  Cytotoxic activity and T cell receptor repertoire in tumor-infiltrating lymphocytes of adrenal cell carcinomas.

Authors:  Y Yamamoto; K Backlin; H Nakagomi; E Halapi; C Juhlin; A Bucht; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

6.  Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.

Authors:  Sreelatha Chalasani; Hemender Singh Vats; Tarit K Banerjee; Alan K McKenzie
Journal:  Clin Med Res       Date:  2009-06

7.  Adrenal cortical carcinoma in Norway, 1970-1984.

Authors:  J A Søreide; K Brabrand; S O Thoresen
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

8.  Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer.

Authors:  Tanweera S Khan; Anders Sundin; Claes Juhlin; Erik Wilander; Kjell Oberg; Barbro Eriksson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

9.  Case studies in hypertension. Adrenal carcinoma.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Sep-Oct       Impact factor: 3.738

Review 10.  Adrenal cortical carcinoma.

Authors:  R P Boushey; A P Dackiw
Journal:  Curr Treat Options Oncol       Date:  2001-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.